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Abstract: Background and aims 
Resection is the most widely used potentially-curative treatment for 
patients with early hepatocellular carcinoma (HCC). However, recurrence 
within 2 years occurs in 30-50% of patients, being the major cause of 
mortality. Here, we describe two models, both based on widely available 
clinical data, which permit risk of early recurrence to be assessed 
before and after resection.   
 
Methods 
3903 patients undergoing surgical resection with curative intent from 6 
different centres were recruited. Two models for early recurrence, one 
using preoperative and one using pre and post-operative data were built 
and internally validated in the Hong Kong cohort. The models were then 
externally validated in European, Chinese and US cohorts.  Two online 
calculators were developed to permit easy clinical application.  
 
Results 
Multivariable analysis identified male, gender, large tumour size, 
multinodular tumour, high Albumin-Bilirubin (ALBI) grade and high serum 
AFP as the key parameters related to early recurrence. Using these 
variables, a pre-operative model (ERASL-pre) gave three risk strata for 
recurrence free survival (RFS) in the entire cohort - low risk: 2-year 
RFS 64.8%, intermediate risk: 2-year RFS 42.5% and high risk: 2-year RFS 
20.7%. Median survival in each stratum was similar between centres and 
the discrimination between the three strata was enhanced in the post-
operative model (ERASL-post) which included 'microvascular invasion'.  
 
Conclusions 
Statistical models, that can predict the risk of early HCC recurrence 
after resection, have been developed, extensively validated and shown to 
be applicable in the international setting. Such models will be valuable 
in guiding surveillance follow-up and in the design of post-resection 
adjuvant therapy trials. 
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ABSTRACT 1 
 2 
Background and aims 3 
Resection is the most widely used potentially-curative treatment for patients with early 4 
hepatocellular carcinoma (HCC). However, recurrence within 2 years occurs in 30-50% of 5 
patients, being the major cause of mortality. Here, we describe two models, both based on 6 
widely available clinical data, which permit risk of early recurrence to be assessed before and 7 
after resection.   8 
 9 
Methods 10 
3903 patients undergoing surgical resection with curative intent from 6 different centres were 11 
recruited. Two models for early recurrence, one using preoperative and one using pre and 12 
post-operative data were built and internally validated in the Hong Kong cohort. The models 13 
were then externally validated in European, Chinese and US cohorts.  Two online calculators 14 
were developed to permit easy clinical application.  15 
 16 
Results 17 
Multivariable analysis identified male, gender, large tumour size, multinodular tumour, high 18 
Albumin-Bilirubin (ALBI) grade and high serum AFP as the key parameters related to early 19 
recurrence. Using these variables, a pre-operative model (ERASL-pre) gave three risk strata 20 
for recurrence free survival (RFS) in the entire cohort - low risk: 2-year RFS 64.8%, 21 
intermediate risk: 2-year RFS 42.5% and high risk: 2-year RFS 20.7%. Median survival in 22 
each stratum was similar between centres and the discrimination between the three strata was 23 
enhanced in the post–operative model (ERASL-post) which included ‘microvascular 24 
invasion’.  25 
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 1 
Conclusions 2 
Statistical models, that can predict the risk of early HCC recurrence after resection, have been 3 
developed, extensively validated and shown to be applicable in the international setting. Such 4 
models will be valuable in guiding surveillance follow-up and in the design of post-resection 5 
adjuvant therapy trials.  6 
 7 
 8 
 9 
 10 
LAY SUMMARY 11 
The most effective treatment of cancer that starts in the liver (hepatocellular carcinoma) is 12 
surgical removal of the tumour but there is often recurrence. In this large international study, 13 
we develop a statistical method that allows clinicians to estimate the risk of recurrence in an 14 
individual patient.  This facility enhances communication with the patient about the likely 15 
success of the treatment and will help in designing clinical trials that aim to find drugs that 16 
decrease the risk of recurrence.  17 
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Introduction 1 
Worldwide, hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the 2 
second most common cause of cancer-related death.(1) There is a wide variety of therapeutic 3 
options for HCC patients, depending on tumour burden, liver function and performance 4 
status.(2) Potentially curative therapy recommended for those patients with very early/early 5 
stage tumour (Barcelona Clinic Liver Cancer [BCLC] 0/A) consists of surgical resection, liver 6 
transplantation or local ablation. Due to scarcity of donor organs, surgical resection and 7 
ablation are the mainstay of curative treatment options in Asian-Pacific countries, which 8 
account for three quarters of all new patients globally.(1) Surgical resection provides better 9 
clinical outcome than local ablation particularly among patients with well-preserved hepatic 10 
function.(3, 4)  11 
 12 
However, tumour recurrence is a major post-operative complication and is generally 13 
classified into early or late recurrence by using 2 years as the cut-off.(5, 6) Early recurrence 14 
(i.e. within 2 years of resection) accounts for more than 70% of tumour recurrence and is 15 
assumed to represent ‘true recurrence’ whereas after this period “recurrences” are assumed to 16 
be largely accounted for by ‘de novo’ tumours.(7) The 2-year recurrence-free survival (RFS) 17 
is about 50% and 30% among and those with BCLC 0 or A tumours, respectively.(7-9) 18 
Identification of patients after potentially curative surgery who are at high risk of recurrence 19 
allows clinicians to provide appropriate surveillance so as to detect recurrent HCC at its 20 
earliest stage, when curative therapy may still be feasible. 21 
 22 
Curative therapy offers much more favourable long-term survival than palliative therapy 23 
among patients with recurrent HCC.(3, 10, 11) Patients at high risk of early recurrence are 24 
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potential candidates for clinical trials of adjuvant therapy although there is no standard of care 1 
for adjuvant therapy for surgically treated HCC patients. (6, 12) (13) (14) (15) 2 
 3 
Currently, there is no consensus as to the optimal tool for risk stratification and this may 4 
partially contribute to failure of clinical trials of adjuvant therapy due to suboptimal patient 5 
selection. Except for the American Joint Committee on Cancer (AJCC) Tumour-Node-6 
Metastasis (TNM), the majority of HCC staging systems are not derived from surgically 7 
managed patients. Their prognostic performances on classifying post-operative early 8 
recurrence have not been fully evaluated. A few models including the Singapore Liver Cancer 9 
Recurrence (SLICER) score, the Korean model, Surgery-Specific Cancer of the Liver Italian 10 
Program (SS-CLIP), have been developed specifically to detect tumour recurrence after 11 
surgical resection but none of them have been externally validated.(8, 9, 16). Moreover, 12 
microvascular invasion is an important component of AJCC TNM, SLICER, SS-CLIP and 13 
Korean models, but only can be evaluated pathologically in the resected specimen after 14 
operation. A prognostic model that only requires parameters that are available pre-operatively 15 
may help surgeons to better select surgical candidates. 16 
 17 
In this study, we employed large cohorts from different countries to develop and validate 18 
prognostic models for surgically treated HCC patients based on readily accessible clinical and 19 
pathological parameters on order to predict early recurrence. Two models were developed: 20 
One included parameters available before surgery so as to allow prediction of early recurrence 21 
pre-operatively, and a second that included parameters available only after resection to give a 22 
more accurate prediction. 23 
 24 
 25 
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Patients and methods 1 
This analysis was reported according to the TRIPOD (Transparent reporting of a 2 
multivariable prediction model for individual prognosis or diagnosis) guidelines(17).  3 
 4 
Patients 5 
In this international retrospective cohort study, a total of 3903 surgically treated HCC patients 6 
from 6 centres in different countries were accrued. These centres comprise Hong Kong (the 7 
Chinese University of Hong Kong), mainland China (the First Affiliated Hospital of Wenzhou 8 
Medical University, Wenzhou; Affiliated Tumour Hospital of Guangxi Medical University, 9 
Nanning), Italy (S.Orsola-Malpighi Hospital, University of Bologna and Gastrointestinal 10 
Surgery, Istituto Nazionale Tumori, Milan), Japan (Ogaki Municipal Hospital), and the 11 
United States (personal experience Sasan Roayaie, New York). All centres fulfilled ethical 12 
requirements (including informed consent) according to local practice and it is our 13 
understanding that such studies do not require formal protocol approval. Inclusion 14 
requirements were that the patients underwent surgical resection of HCC with curative intent. 15 
Patients who underwent resection for tumour rupture were excluded. All resections were 16 
undertaken after the year 2000 except for the Japanese cohort where patients were recruited 17 
between 1990 and 2014. There was no statistically significant difference in survival or 18 
recurrence rates between those treated before and after the year 2000. Table 1 summarizes 19 
baseline characteristics of the patient cohorts. Patients with missing data were excluded from 20 
the analysis. 21 
 22 
The pre-operative and post-operative ERASL models were built on the Hong Kong dataset 23 
(dates 2001-2012) and then internally validated on a similar population from Hong Kong 24 
(dates 2013-2015). We then validated the models externally on datasets from mainland China, 25 
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Italy, Japan and the United States. The criteria for surgical resection in Eastern centres (Hong 1 
Kong, mainland China and Japan) included: good liver function indicated by a 15-min ICG 2 
retention rate of <30% (Hong Kong and Japan) or Child-Pugh A with presence of appropriate 3 
residual liver volume determined by volumetric computed tomography and/or magnetic 4 
resonance imaging (mainland China); a single HCC, or not more than 3 HCCs, located in the 5 
same segment; less than 85 years of age (<75 years in Wenzhou); and absence of extrahepatic 6 
metastasis.  In Italy(18), and the United States, a personalized approach was undertaken based 7 
on multidisciplinary discussion.  8 
 9 
All clinical and laboratory parameters were collected and reviewed from patients’ records. 10 
The Albumin-Bilirubin (ALBI) score was computed by the formula, −0.085× (albumin g/l) + 11 
0.66×log (bilirubin µmol/l).(19) Patients were stratified into three groups according to 12 
previously described cut-offs resulting in three grades: ALBI grade 1 (≤−2.60), grade 2 13 
(>−2.60 to −1.39) and grade 3 (>−1.39).(19)  Macrovascular invasion was defined as vascular 14 
invasion of large vessels detectable radiologically, whereas microvascular invasion was 15 
vascular invasion of small vessels only identifiable histologically. There was no 16 
microvascular invasion data available in the Nanning cohort, hence this cohort was used for 17 
validation of the pre-operative model only. Patients in the Hong Kong cohort were classified 18 
according to 7th edition of AJCC TNM, Korean model (including 5 parameters: gender, 19 
tumour volume, microvascular invasion, serum albumin and platelet count) and SLICER 20 
score (using 8 parameters: symptomatic, cirrhotic background, Child-Pugh grade, surgical 21 
resection margin distance, tumour size, tumour number, vascular invasion, and preoperative 22 
serum alpha fetoprotein AFP).(8, 9) After tumour resection, all patients were followed up 23 
according to institutional practice including clinical assessment serum AFP 6-monthly and 24 
ultrasound or contrast-enhanced computed tomography every 6 to 12 months. RFS was 25 
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defined as the time from date of curative surgery to the time of recurrence. Patients with no 1 
recurrent disease were censored at the last time at which they were known to be recurrence 2 
free. Those dying within 90 days of surgery were not excluded from the analysis. The 90-day 3 
mortality rate was 0.6% (Hong Kong derivation cohort), 0.7% (Hong Kong internal validation 4 
cohort), 1.5% (Japan), 7.7% (the United States), 0% (Wenzhou, China), 0.9% (Nanning, 5 
China) and 2.7% (Italy). 6 
 7 
Statistical analyses 8 
All statistical analyses were performed in R version 3.2.5 (R Foundation for Statistical 9 
Computing, Vienna, Austria) or Stata/SE 14.2 (StataCorp, Texas, USA).   Continuous 10 
variables were reported as mean (with standard deviation [SD]) or median (with interquartile 11 
range [IQR]), the latter for variables with highly skewed distributions. Categorical variables 12 
were presented as percentages.  We constructed two models to predict early recurrence using 13 
the derivation cohort. One model, the pre-operative model, was based on clinicopathological 14 
parameters available before surgery; the second, the post-operative model, was developed on 15 
all available parameters. Clinicopathological parameters that were shown to be potentially 16 
relevant (with p<0.2 in the univariable Cox regression) were considered for generating the 17 
multivariable Cox model. The multivariable Cox regression model was built by stepwise 18 
backward selection of variables significant at the 10% level. A number of potentially 19 
clinically plausible interactions were also included in the selection. Model β-estimates were 20 
used to compute hazard ratios and calculate the risk score for prediction of early recurrence. 21 
The risk score was a weighted sum of those significant parameters, of which the weights were 22 
β-estimatescoefficients from the multivariable Cox regression analysis. The proportional 23 
hazards assumption of the models was tested by examining the plots of scaled Schoenfeld 24 
residuals against time for each variable in the models. By applying previously reported cut-25 
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offs (50
th
 and 85
th
 centile) to the score (20), three risk groups (low, intermediate and high) 1 
were generated.  Kaplan-Meier (KM) survival curves according to the risk groups were 2 
plotted for each of the derivation and validation sets. Median RFS, hazard ratio (HR), and 3 
percentage RFS at 2 years were also calculated for each risk group. 4 
 5 
Model discrimination was assessed via the “regression on the prognostic index (PI)” approach 6 
(20), also known as the “calibration slope”. The regression coefficient on the risk score in the 7 
validation sets was estimated and compared to that of the derivation set, which is by 8 
construction exactly 1. If the validation set coefficients equals to 1, <1 or >1, they reflect as 9 
good as, poorer or better discrimination respectively in relation to the derivation set. 10 
 11 
Prognostic performance Model discrimination of the models in the derivation and validation 12 
sets was also measured by the Harrell’s c-index, Gönen & Heller’s K, Royston-Sauerbrei’s 13 
R
2
D and time dependent receiver operating characteristic curve (tdAUC).(20-22) 14 
Cumulative/dynamic tdAUC was evaluated because we aimed to discriminate between 15 
individuals experiencing recurrence and those recurrence-free prior to 2 years. The 16 
prognosticDiscriminatory performance of our newly established models wasere also 17 
compared to AJCC TNM, the Korean model and the SLICER in the Hong Kong derivation 18 
and validation sets. 19 
 20 
Models were calibrated using calibration plots and comparing model-predicted versus 21 
observed survival curves. 22 
 23 
Calibration plots were applied to the derivation and validation sets.  Estimates of predicted 24 
versus observed values were generated via bootstrapping (with 200 resampling). In order to 25 
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obtain a continuous calibration plot for a specific survival time, regression-spline 1 
interpolations(23, 24) were used to generate a continuous observed survival probability. The 2 
resulting plot was also “optimism-corrected” by a method described by Harrell et al (25).  3 
 4 
Model-predicted mean survival curves were generated by applying fractional polynomial 5 
regression to approximate the log baseline cumulative hazard function as a smooth function of 6 
time (20). Model-predicted versus KM estimates was then plotted according to each risk 7 
group in the derivation and validation sets. 8 
 9 
 10 
Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           11 
Construction of the model predicting early recurrence 12 
In the derivation cohort, 451 patients receiving curative surgery between 2001 and 2012 were 13 
recruited after excluding 44 patients who were complicated by tumour rupture before 14 
operation. There were only two patients with missing data on at least one of the variables. 15 
ALBI grade 2 and ALBI grade 3 were group together due to low sample size in the latter. One 16 
hundred and sixty-two patients (35.9%) developed recurrence within 2 years of surgery. 17 
Among 18 clinicopathological parameters analysed, 12 were found to be potentially relevant 18 
with p<0.2 in the univariable Cox regression analysis (Supplementary table 1). Four of these, 19 
namely positive resection margin, ALT, ALP and INR, had to be excluded because they were 20 
not available in all of the external validation cohorts. Two parameters, namely (intraoperative 21 
blood loss and microvascular invasion) were only recorded after the operation and hence 22 
excluded in the multivariable analysis for establishing the pre-operative model, whereas all 8 23 
parameters were employed for building the post-operative model. By the stepwise 24 
multivariable analysis, independent parameters were identified for both models (Table 2). We 25 
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did not detect any significant violation of the proportional hazard assumption, assessed by 1 
scaled Schoenfeld residuals on functions of time. 2 
 3 
The pre-operative model, Early Recurrence After Surgery for Liver tumour (ERASL-pre) 4 
score, was constructed; its formula shown in Table 2. The RFS of an individual patient with a 5 
particular ERASL-pre score can be estimated by applying a previously described formula 6 
(Supplementary table 2)(26). Using 2.558 and 3.521 as the cut-off values of the ERASL-pre 7 
score (which correspond to the 50
th
 and 85
th
 centile of the score in the derivation cohort, 8 
respectively), three prognostically distinct groups were stratified (derivation cohort): low-risk 9 
(2-year RFS: 76.3%), intermediate-risk (2-year RFS: 57.4%; P<0.001 in comparison to low-10 
risk) and high-risk (2-year RFS: 29.5%; P<0.001 in comparison to intermediate-risk) (Table 3; 11 
Fig.1A). The ERASL-pre score could identify 15% of patients at particularly high-risk 12 
(70.5%) of early recurrence. For routine clinical application a simple online calculator that 13 
takes the variables from the model(s) and returns the ERASL scores, the risk group and the 14 
recurrence free survival likelihood at any time between 1 and 24 months after resection for 15 
the individual patient was developed and is available at: 16 
https://jscalc.io/calc/Fu3bREKIInObXCtj 17 
 18 
 19 
Similarly, the post-operative model, ERASL-post, was built according to the formula for 20 
score shown in Table 2. As in ERASL-pre, the RFS of an individual patient with a particular 21 
ERASL-post score can be estimated (Supplementary Table 2). Using the 50
th
 and 85
th
 centiles 22 
of the ERASL-post scores in the derivation cohort, 2.332 and 3.445 respectively, as cut-off 23 
values, three prognostically distinct groups were classified (derivation cohort): low-risk (2-24 
year RFS: 80.9%), intermediate-risk (2-year RFS: 50.9%; P<0.001 in comparison to low-risk) 25 
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and high-risk (2-year RFS: 30.0%; P<0.001 in comparison to intermediate-risk) (Table 4; Fig. 1 
2A). The ERASL-post score was able to identify 15% of patients at high-risk (70.0%) of early 2 
recurrence. 3 
 4 
 5 
Internal and external validation of the ERASL models 6 
Both ERASL models were first validated in an internal validation cohort, which was 7 
composed of 130 patients with HCC receiving curative surgery between 2013 and 2015 in 8 
Hong Kong. There was no missing data in the internal validation set. By using the cut-off 9 
values established in the derivation cohort (2.558 and 3.521), the ERASL-pre model 10 
categorized patients into low-risk (2-year RFS: 77.1%), intermediate-risk (2-year RFS: 67.5%; 11 
P=0.313 in comparison to low-risk) and high-risk (2-year RFS: 19.4%; P<0.001 in 12 
comparison to intermediate-risk) groups (Table 3; Fig. 1B). Similarly, patients from the 13 
independent external validation cohorts from five centres (after exclusion of patients with 14 
incomplete data on predictor parameters), Japan (n=582), the United States (n=548); 15 
Wenzhou, China (n=98); Nanning, China (n=1198); and Italy (n=742), could be also 16 
categorized into three separate risk groups by the ERASL-pre model (Fig. 1C-F) (Table 3). 17 
Likewise, the ERASL-post model subdivided patients from the internal and external 18 
validation cohorts into three distinct risk groups (Fig. 2C-F) (Table 4).   19 
 20 
Assessing model discrimination and prognostic performance 21 
Overall, the regression coefficient on the ERASL-pre and post scores showed good 22 
discrimination relative to the derivation set across validation cohorts (coefficient figures 23 
ranging from 0.70 to 1.21) although discrimination was less good in the Italian cohort 24 
(ERASL-pre: 0.59, ERASL-post: 0.65).   25 
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 1 
Similarly the prognostic discriminatory performance of the models was compared via 2 
Harrell’s c-index, Gönen & Heller’s K, Royston-Sauerbrei’s R2D and tdAUC as shown in 3 
Table 5. Both models showed similar performance in the derivation and internal validation 4 
sets. In the external validation cohorts, good discrimination was also observed, although there 5 
was a slight deterioration in the measurement figures, which was most pronounced in the 6 
Italian cohort.  7 
The prognostic discriminatory performance of both ERASL models exceeded those of AJCC 8 
TNM, the Korean model and the SLICER score in predicting early recurrence (Table 5). By 9 
including microvascular invasion, ERASL-post showed a better performance than ERASL-10 
pre.  11 
 12 
Calibration 13 
The calibration plots showed an overall good agreement between the predictions made by the 14 
ERASL pre and ERASL post models and observed outcome in the Hong Kong derivation and 15 
internal validation sets (Figure 3A-F).  This was also the case for the external validation sets 16 
(Supplementary figure 1 A-H). 17 
Plots of KM estimates versus ERASL-pre predicted survival curves were overall very similar 18 
(Supplementary figures 2 [A-F]), with the exception of the Chinese cohort, the lowest risk 19 
groups of the Japanese, U.S. and Italian cohorts where the ERASL-pre model overestimated 20 
RFS.  In the ERASL-post model, there was also an overall agreement between KM estimates 21 
and model-predicted survival probabilities (Supplementary figures 3 [A-F]) with the 22 
exception of model overestimation of RFS in the low risk categories of Japan and Italy. 23 
Nevertheless, despite some of discrepancies between predicted and KM estimates in some of 24 
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the risk groups, the stratification of each of the cohorts into three groups according to risk was 1 
maintained. 2 
 3 
KM survival plots according for the ERASL-pre and post risk groups involving the entire 4 
cohort are shown in Supplementary figure 4. 5 
 6 
Discussion 7 
Two models (ERASL-pre and ERASL-post) that enable risk assessment of early recurrence 8 
before and after resection have been derived and validated in a large international multicentre 9 
study of surgically-treated HCC patients. Although they were derived from a hepatitis B 10 
prevalent region (Hong Kong), their application was generalizable to regions with 11 
predominant hepatitis C (Japan and Italy) or mixed aetiologies (the United States). They were 12 
capable of stratifying patients into three groups with discrete risk profiles. Using the ERASL-13 
pre model, the high-risk group consisted of 13.1% of the patients among the entire cohort but 14 
accounted for 79.3% of those who developed early recurrence, whereas the low-risk and 15 
intermediate-risk groups comprised of 46.1% and 40.8% of patients but only 35.2% and 16 
57.5% of those who developed early recurrence, respectively (Supplementary Fig. 4). 17 
Correspondingly, the ERASL-post also identified a high-risk group comprising 12.3% of 18 
patients among the entire cohort with 73.9% chance of early recurrence (Supplementary Fig. 19 
4). Both models are clinically relevant because they allow the identification of a small, but 20 
potentially manageable, portion of patients at high risk in the development of early recurrence. 21 
Although it may not be considered appropriate to exclude those patients at high-risk of early 22 
recurrence from curative surgery, more intensive surveillance might be offered and they 23 
would be candidates for clinical trials of adjuvant therapy. The ERASL models are also 24 
reliable as they are the first models designed to predict early recurrence that have been 25 
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externally validated in different geographic regions and with different etiological factors. 1 
Despite, a minor degree of discrepancy between predicted and KM estimates (Supplementary 2 
figure 2 and 3), the stratification of each of the cohorts into three groups according to risk was 3 
maintained. Although the ERASL-pre model is the first to be applicable solely on the basis of 4 
pre-treatment parameters, it still appears to outperform existing models which require 5 
additional postoperatively acquired variables. It may also help surgeons to identify those 6 
surgical candidates at high risk of early recurrence before operation. Furthermore, the models 7 
only require simple, readily available clinicopathological parameters.  8 
 9 
Vascular invasion, in particular microvascular invasion, is a well-known independent 10 
prognostic factor associated with more advanced tumour stage, tumour progression and 11 
poorer clinical outcome.(27) Microvascular invasion is the single parameter shared by 12 
ERASL-post, SLICER, SS-CLIP and Korean models.(8, 9, 16) It is also an essential 13 
component in the AJCC TNM system. The incidence of microvascular invasion was 33.1% 14 
(26.8 – 73.1%) in our current cohorts. Assessment of microvascular invasion currently relies 15 
on histological examination of surgically resected specimens by pathologists. Subjectivity and 16 
sampling error are undoubtedly potential problems in evaluating microvascular invasion. 17 
Serum tumour markers, pre-operative imaging and gene signatures have been investigated as 18 
possible approaches to prediction of microvascular invasion but none has yet been validated 19 
and they are not routinely applicable in daily clinical practice.(27) Histological classifications 20 
of microvascular invasion have been proposed but none of them are universally accepted and 21 
their clinical significance has yet to be validated.(28-30) Hence, for simplicity and better 22 
acceptance, only the presence/absence of microvascular invasion was used in the ERASL-23 
post model. Other parameters that might influence RFS could be added to our models 24 
although it is evident that extent of surgical resection, resection margin and degree of blood 25 
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loss did not emerge as independent prognostic variables. Nonetheless, the models give 1 
strikingly clear-cut risk groups and show very similar results within each of the validation sets. 2 
Adding more prognostic variables is unlikely to improve our models’ performance 3 
significantly other than further narrowing the current confidence intervals. 4 
 5 
Liver (dys)function is another independent prognosticator to predict tumour recurrence used 6 
in ERASL, SLICER and SS-CLIP models.(8, 16) To evaluate liver dysfunction, our ERASL 7 
models used ALBI grade, whereas the latter two models used Child-Pugh grade. The ALBI 8 
grade is our recently proposed, widely-validated and evidence-based refinement of the Child-9 
Pugh grade.  (19, 31) The majority of surgically treated HCC patients belong to Child-Pugh A, 10 
which accounted for more than 95% of patients in our current dataset and SLICER and SS-11 
CLIP and Korean cohorts, respectively.(8, 9, 16) We previously demonstrated that Child-12 
Pugh A patients were composed of two prognostically distinct subgroups as classified by the 13 
ALBI grade.(4, 19) Therefore, ALBI grade rather than Child-Pugh grade was incorporated in 14 
our ERASL models to provide better discriminatory power. However, the underlying reason 15 
of the association between liver dysfunction and early recurrence remains unclear. 16 
 17 
Tumour recurrence may represent either intrahepatic metastases or development of de-novo 18 
tumours. Time of recurrence is one of the factors that has been proposed to distinguish these 19 
two entities,(32, 33) although the exact differentiation requires assessment of recurrence 20 
clonality by genetic/genomic analyses.(34, 35) Early recurrence is generally believed to 21 
represent pre-existing intrahepatic metastasis, whereas late recurrence is regarded as de-novo 22 
tumour. A cut-off of 2 years has been generally adopted to classify early and late 23 
recurrence.(6) Our findings echo other studies in that early and late tumour recurrence are two 24 
distinct entities associated with different risk factors.(7, 32, 36) Early recurrence is mainly 25 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
determined by aggressive characteristics of the primary (resected) tumour such as tumour size, 1 
tumour multiplicity, vascular invasion and higher serum AFP level. These associations 2 
support the contention that early recurrence is likely to result from intrahepatic metastasis 3 
disseminated from the primary tumour. In contrast, late relapse is primarily associated with 4 
aetiology and cirrhotic background, which are well-established risk factors of 5 
hepatocarcinogenesis and provide fertile soil for development of de-novo tumours.(2, 6, 37)  6 
 7 
There are limitations to our study. Our models, at first sight, may appear complex and 8 
difficult to apply at the bedside, but our simple online calculator overcomes this problem. The 9 
online calculators, by providing a quantitative measure of recurrence risk at any post-10 
operative time point, are an important step in our ultimate goal of providing personalized 11 
prognostication. Antiviral treatment has not been included in our models because it was not 12 
recorded in all of our cohorts. However, although the use of antiviral treatment for hepatitis 13 
B-related HCC has been consistently shown to improve overall survival, its effect on post-14 
operative recurrence prevention is still inconclusive.(38-40) Reduction of tumour recurrence 15 
by antiviral agents on hepatitis C-related HCC is also controversial.(41, 42) Third, tumour 16 
size and number were measured radiologically or pathologically in different centres. 17 
Although there might be some variations in tumour size depending on the method of 18 
assessment, the discrepancies are unlikely to be clinically significant. 19 
 20 
In summary, tumour recurrence after curative surgery for HCC is a serious and common 21 
complication. Our ERASL models are clinically relevant, externally validated and offer 22 
powerful tools to predict early recurrence. Further prospective studies are required to explore 23 
the clinical applicability of ERASL models in patient allocation for more frequent follow-up 24 
and clinical trials for adjuvant therapy. We are currently developing a more general 25 
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prognostic model that is applicable to both early and late recurrence, and the performance of 1 
the ERASL models is being prospectively evaluated in an adjuvant clinical trial.   2 
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Figure legends 1 
Fig. 1. Recurrence-free survival (RFS) according to risk groups defined by the ERASL-2 
pre model. Kaplan-Meier plots for RFS in the low, intermediate and high risk groups of the 3 
ERASL-pre model in each of  (A) Hong Kong (derivation), (B) Hong Kong (internal 4 
validation), (C) Japan, (D) the United States, (E) China and (F) Italy cohorts. Median RFS, 5 
hazard ratios (with p-values) and percentage RFS at two years, are reported in Table 3. 6 
 7 
Fig. 1. Recurrence-free survival (RFS) according to risk groups defined by the ERASL-8 
post model. Kaplan-Meier plots for RFS in the low, intermediate and high risk groups of the 9 
ERASL-post model in each of (A) Hong Kong (derivation), (B) Hong Kong (internal 10 
validation), (C) Japan, (D) the United States, (E) China and (F) Italy cohorts. Median RFS, 11 
hazard ratios (with p-values) and percentage RFS at two years, are reported in Table 4. 12 
 13 
Fig. 3. Calibration plots for the ERASL-pre and ERASL-post models in predicting 2-14 
year recurrence-free survival (RFS). (A, B) Hong Kong (derivation) cohort and (C, D) 15 
Hong Kong (internal validation) cohort. Thick dashed line: observed, solid thin line: 16 
optimism corrected. 17 
1 
 
Table 1: Baseline characteristics of patients. 
  
 Variables 
Derivation cohort Validation cohorts 
Hong Kong 
n=451 
Hong Kong 
n=130 
Japan 
n=615 
The United 
States 
n=661 
Wenzhou, 
China 
n=100 
Nanning, 
China 
n=1204 
Italy 
n=742 
Patient factors/Laboratory parameters 
Male gender, n(%) 387 (85.8) 107 (82.3) 469 (76.3) 517 (78.2) 86 (86.0) 1042 (86.5) 
578 (77.9), 
n=742 
Age [years, mean (SD)] 
56 (10.7), 
n=451 
60 (9.2), 
n=130 
66 (9.3), n=615 
60 (11.7), 
n=661 
56 (10.9), 
n=100 
49 (11.4), 
n=1204 
66 (9.1), 
n=742 
        
Etiology n=451 n=130 n=614 n=661 n=100 n=1204 n=742 
Hepatitis B 380 (84.3) 107 (82.3) 126 (20.5) 286 (43.3) 89 (89.0) 1026 (85.2) 154 (20.8) 
Hepatitis C 18 (4.0) 10 (7.7) 362 (59.0) 217 (32.8) 1 (1.0) 12 (1.0) 408 (55.0) 
Other 53 (11.8) 13 (10.0) 126 (20.5) 158 (23.9) 10 (10.0) 166 (13.8) 180 (24.3) 
        
Child-Pugh grade, n(%) n=451 n=130 n=612 n=624 n=100 n=1204 n=742 
A 442 (98.0) 127 (97.7) 577 (94.3) 590 (94.6) 63 (63.0) 1154 (95.9) 697 (93.9) 
B 9 (2.0) 3 (2.3) 35 (5.7) 34 (5.5) 35 (35.0) 50 (4.2) 45 (6.1) 
C 0 (0) 0 (0) 0 (0) 0 (0) 2 (2.0) 0 (0) 0 (0) 
        
ALBI grade, n(%) n=451 n=130 n=612 n=622 n=100 n=1204 n=742 
1 329 (73.0) 99 (76.2) 356 (58.2) 409 (65.8) 51 (51.0) 829 (68.9) 396 (53.4) 
2 119 (26.4) 30 (23.1) 253 (41.3) 197 (31.7) 45 (45.0) 373 (31.0) 338 (45.6) 
3 3 (0.7) 1 (0.8) 3 (0.5) 16 (2.6) 4 (4.0) 2 (0.2) 8 (1.1) 
        
Albumin [g/L, mean (SD)] 
40 (4.4), 
n=451 
41 (4.5), 
n=130 
40 (4.9), n=612 
40 (5.7), 
n=623 
39 (5.9), 
n=100 
41 (4.4), 
n=1204 
40 (5.2), 
n=742 
Bilirubin [µmol/L, median 
(IQR)] 
10 (7, 13), 
n=451 
9 (7, 13), 
n=130 
12.0 (9, 15), 
n=613 
12 (9, 15), 
n=626 
14 (10, 18), 
n=100 
12 (9, 16), 
n=1204 
15 (12, 22), 
n=742 
AFP [µg/L, median (IQR)] 
52.1 (5.4, 
585.0), n=451 
20.0 (4.0, 
411.0), n=130 
13.0 (5.0, 
93.0), n=607 
45.5 (7.1, 
756.0), n=564 
175.6 (7.2, 
768.8), 
n=100 
139.0 (10.2, 
539.7), n=1204 
12.3 (4.6, 
70.0), n=742 
Tumor characteristics 
Tumor size [mm, median 
(IQR)] 
40 (25-60), 
n=451 
30 (20, 55), 
n=130 
28 (18, 44), 
n=609 
50 (30, 85), 
n=651 
50 (30, 70), 
n=100 
60 (40, 98), 
n=1204 
35 (23, 50), 
n=742 
Solitary tumor, n(%) 
350 (77.6), 
n=451 
95 (73.1), 
n=130 
489 (80.2), 
n=610 
514 (78.5), 
n=655 
84 (85.7), 
n=98 
885 (71.3), 
n=1199 
573 (77.2), 
n=742 
        
Tumor differentiation n=451 n=130 n=599 n=618 n=100 Not available n=582 
Well 76 (16.9) 21 (16.2) 146 (24.4) 134 (21.7) 18 (18.0) Not available 79 (13.6) 
Moderate 318 (70.5) 91 (70.0) 408 (68.1) 318 (51.5) 55 (55.0) Not available 257 (44.2) 
Poor 57 (12.6) 18 (13.9) 45 (7.5) 166 (26.9) 27 (27.0) Not available 246 (42.3) 
        
Microvascular invasion 
121 (26.8), 
n=451 
38 (29.3), 
n=130 
166 (27.7), 
n=599 
476 (73.1), 
n=651 
48.0 (48.0), 
n=100 
Not available 
366 (49.3), 
n=742 
Macrovascular invasion 
38 (8.4), 
n=451 
9 (6.9), n=130 44 (7.4), n=599 
186 (28.6), 
n=651 
9 (9.0), n=100 
205 (17.0), 
n=1203 
0 (0), n=742 
Clinical outcome 
Recurrence with 2 years, 
n(%) 
162 (35.9), 
n=451 
43 (33.1), 
n=130 
245 (40.0), 
n=613 
284 (43.0), 
n=661 
30 (30.0), 
n=100 
511 (42.4), 
n=1204 
295 (39.8), 
n=742 
Recurrence-free survival, 
months (95% CI) 
66.7 (48.0, 
83.1), n=451 
Not reached,  
n=130 
27.6 (24.0, 
33.8), n=611 
21.8 (18.2, 
27.9), n=660 
Not reached,  
n=100 
11.0 (10.0, 
13.0), n=1204 
27.7 (24.1, 
32.6), n=742 
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; CI, confidence interval; IQR, interquartile range; RFS, recurrence-free survival; SD, standard 
deviation. Mean (standard deviation) presented for normally distributed continuous variables, while median (interquartile range) was given to 
those with non-normally distributed continuous variable. 
Table
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Table 2: Multivariable Cox regression analyses of prognostic factors in the derivation cohort 
  
Variable 
ERASL-pre ERASL-post 
Hazard ratio (95% 
C.I.) 
β-estimate (95% 
C.I.) 
P-value* 
Hazard ratio (95% 
C.I.) 
β-estimate (95% 
C.I.) 
P-value* 
Gender       
                                          Female ref Ref  ref ref  
                                          Male 2.265 (1.305, 3.932) 0.818 (0.266, 1.369) 0.004 1.969 (1.128, 3.434) 0.677 (0.121, 1.234) 0.017 
ALBI grade       
                                          1 ref Ref  ref ref  
                                          2 or 3 1.563 (1.128, 2.166) 0.447 (0.121, 0.773) 0.007 1.581 (1.142, 2.190) 0.458 (0.133, 0.784) 0.006 
Microvascular invasion       
                                          No Not applicable Not applicable NA ref ref  
                                          Yes Not applicable Not applicable NA 1.938 (1.353, 2.775) 0.661 (0.302, 1.021) <0.0001 
ln(AFP) 1.106 (1.053, 1.161) 0.100 (0.052, 0.149) <0.0001 1.086 (1.033, 1.141) 0.082 (0.032, 0.132) 0.001 
ln(Tumor size) 1.785 (1.374, 2.320) 0.580 (0.318, 0.841) <0.0001 1.570 (1.202, 2.052) 0.451 (0.184, 0.719) 0.001 
Tumor number (1 vs 2/3 vs >3) 1.636 (1.350, 1.983) 0.492 (0.300, 0.685) <0.0001 1.461 (1.194, 1.789) 0.379 (0.177, 0.582) <0.0001 
ERASL-pre score = 0.818 x Gender (0: Female, 1: Male) + 0.447 x Albumin-Bilirubin (ALBI) grade (0: Grade 1; 1: Grade 2 or 3) + 0.100 x ln(Serum AFP in 
µg/L) + 0.580 x ln(Tumor size in cm) + 0.492 x Tumor number (0: Single; 1: Two or three; 2: Four or more)   
Cut-offs to generate the risk groups: ≤2.558 (low), >2.558 to ≤3.521 (intermediate), >3.521 (high)  
 
ERASL-post score = 0.677 x Gender (0: Female, 1: Male) + 0.458 x Albumin-Bilirubin (ALBI) grade (0: Grade 1; 1: Grade 2 or 3) + 0.661 x microvascular 
invasion (0: no, 1: yes) + 0.082 x ln(Serum AFP in µg/L) + 0.451 x ln(Tumor size in cm) + 0.379 x Tumor number (0: Single; 1: Two or three; 2: Four or 
more)   
Cut-offs to generate the risk groups: ≤2.332 (low), >2.332 to ≤3.445 (intermediate), >3.445 (high) 
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; CI, confidence interval. *Wald test 
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Table 3: Median recurrence-free survival (RFS), hazard ratio and 2-year RFS according to each risk group 
as defined by ERASL-pre model 
Cohort Group  n 
Median recurrence-free 
survival, months (95% C.I.) 
Hazard ratio  
(95% C.I.) 
P-value* 
2-year RFS, % 
(95% CI) 
Hong Kong 
(derivation set) 
Low 226 84.90 (71.00, not reached) 1  76.34 (70.14, 81.42) 
Intermediate 158 68.20 (23.20, 102.90) 2.05 (1.42, 2.96) <0.0001 57.36 (49.04, 64.82) 
High 67 7.80 (4.90, 11.80) 5.63 (3.78, 8.40) <0.0001 29.46 (18.95, 40.74) 
Hong Kong 
(validation set) 
Low 76 Not reached 1  77.09 (65.70, 85.12) 
Intermediate 35 33.40 (18.40, not reached) 1.48 (0.69, 3.16) 0.313 67.46 (48.95, 80.50) 
High 19 6.20 (4.20, 11.30) 6.51 (3.22, 13.19) <0.0001 19.74 (5.51, 40.32) 
Japan 
Low 404 36.00 (31.20, 48.00) 1  62.52 (57.15, 67.42) 
Intermediate 158 18.00 (14.40, 24.00)  2.03 (1.55, 2.67) <0.0001 39.73 (31.59, 47.74) 
High 34 4.80 (2.40, 14.40) 4.36 (2.79, 6.80) <0.0001 19.87 (7.44, 36.61) 
U.S. 
Low 242 41.86 (30.00, 54.86) 1  64.66 (57.65, 70.80) 
Intermediate 214 15.31 (12.42, 20.80) 2.08 (1.54, 2.80) <0.0001 41.59 (34.17, 48.83) 
High 93 5.45 (4.24, 10.64) 4.20 (2.95, 5.99) <0.0001 25.66 (15.87, 36.61) 
China (Nanning 
and Wenzhou) 
Low 366 41.00 (30.00, 50.00) 1  60.86 (53.26, 67.61) 
Intermediate 687 12.53 (10.00, 15.00) 2.21 (1.72, 2.83) <0.0001 34.88 (30.06, 39.74) 
High 244 4.00 (4.00, 5.00) 4.43 (3.38, 5.82) <0.0001 13.55 (8.52, 19.74) 
Italy 
Low 421 36.15 (30.76, 44.70) 1  60.51 (55.22, 65.37) 
Intermediate 284 23.16 (19.11, 25.59) 1.53 (1.21, 1.93) <0.0001 47.20 (40.74, 53.38) 
High 37 11.22 (4.51, 18.09) 2.71 (1.68, 4.37) <0.0001 31.77 (15.47, 49.44) 
All 
Low 1735 45.76 (40.79, 49.20) 1  64.82 (62.23, 67.28) 
Intermediate 1536 18.00 (16.30, 20.60) 2.07 (1.85, 2.33) <0.0001 42.46 (39.56, 45.33) 
High 494 5.45 (4.80, 6.41) 4.67 (4.05, 5.38) <0.0001 20.70 (16.67, 25.04) 
CI, confidence interval. *Wald test 
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Table 4: Median recurrence-free survival (RFS), hazard ratio and 2-year RFS according to each risk group 
as defined by ERASL-post model 
Cohort Group  n 
Median recurrence-free 
survival, months (95% C.I.) 
Hazard ratio  
(95% C.I.) 
P-value* 
2-year RFS, % 
(95% C.I.) 
Hong Kong 
(derivation set) 
Low 226 102.90 (78.90, not reached) 1  80.87 (75.02, 85.49) 
Intermediate 158 25.70 (18.60, 72.50) 3.11 (2.13, 4.55) <0.0001 50.89 (42.58, 58.61) 
High 67 9.00 (5.70, 12.60) 6.79 (4.47, 10.33) <0.0001 29.85 (19.44, 40.97) 
Hong Kong 
(validation set) 
Low 76 Not reached 1  82.38 (71.55, 89.39) 
Intermediate 36 27.80 (13.20, not reached) 3.00 (1.44, 6.23) 0.003 54.90 (37.16, 69.54) 
High 18 6.20 (4.40, 11.30) 8.45 (3.93, 18.17) <0.0001 18.52 (3.98, 41.40) 
Japan 
Low 369 37.20 (31.22, 48.00) 1  63.28 (57.67, 68.35) 
Intermediate 167 20.40 (16.80, 25.20) 1.89 (1.43, 2.49) <0.0001 42.17 (34.09, 50.01) 
High 46 6.00 (3.60, 14.40) 4.78 (3.24, 7.05) <0.0001 16.73 (6.89, 30.26) 
U.S. 
Low 154 70.80 (42.45, 108.62) 1  73.55 (65.21, 80.20) 
Intermediate 275 18.30 (15.31, 25.69) 2.69 (1.86, 3.90) <0.0001 44.94 (38.31, 51.33) 
High 119 6.37 (4.50, 8.61) 6.09 (4.05, 9.18) <0.0001 25.91 (16.91, 35.85) 
China 
(Wenzhou only) 
Low 31 Not reached 1  87.10 (69.19, 94.95) 
Intermediate 55 60.83 (34.13, not reached) 2.65 (0.89, 7.89) 0.079 68.87 (54.78, 79.37) 
High 12 9.47 (6.77, not reached) 6.91 (2.02, 23.66) 0.002 40.00 (13.52, 65.73) 
Italy 
Low 325 40.46 (33.35, 46.09) 1  66.32 (60.47, 71.51) 
Intermediate 366 21.88 (17.47, 24.57) 1.86 (1.45, 2.39) <0.0001 45.98 (40.28, 51.49) 
High 51 11.78 (8.03, 19.11) 3.31 (2.16, 5.07) <0.0001 29.23 (15.27, 44.71) 
All 
Low 1181 54.30 (48.00, 64.50) 1  71.03 (68.18, 73.67) 
Intermediate 1057 22.57 (19.84, 24.57) 2.18 (1.89, 2.51) <0.0001 47.51 (44.23, 50.72) 
High 313 8.10 (6.41, 10.30) 4.92 (4.11, 5.90) <0.0001 26.10 (20.77, 31.72) 
CI, confidence interval. *Wald test 
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Table 5: Prognostic performance of the ERASL models. 
Measure of 
discrimination 
Cohort 
ERASL-pre 
(SE) 
ERASL-post 
(SE) 
AJCC TNM 
(SE) 
Korean (SE) SLICER (SE) 
*Harrell’s c-index 
Hong Kong (Derivation) 0.713 (0.021) 0.735 (0.020) 0.693 (0.018) 0.627 (0.023) 0.716 (0.023) 
Hong Kong (Validation) 0.708 (0.043) 0.723 (0.043) 0.685 (0.039) 0.642 (0.090) 0.717 (0.045) 
Japan 0.656 (0.018) 0.668 (0.018)    
U.S. 0.669 (0.019) 0.698 (0.018)    
China 0.672 (0.012) 0.725 (0.056)    
Italy 0.601 (0.016) 0.616 (0.016)    
*Gönen & Heller’s K 
Hong Kong (Derivation) 0.689 (0.015) 0.695 (0.014) 0.638 (0.012) 0.599 (0.017) 0.667 (0.014) 
Hong Kong (Validation) 0.692 (0.027) 0.693 (0.027) 0.654 (0.025) 0.614 (0.031) 0.695 (0.028) 
Japan 0.631 (0.016) 0.640 (0.016)    
U.S. 0.645 (0.017) 0.668 (0.017)    
China 0.645 (0.010) 0.695 (0.047)    
Italy 0.599 (0.016) 0.616 (0.015)    
*Royston-Sauerbrei’s 
R2D 
Hong Kong (Derivation) 0.316 (0.050) 0.354 (0.050) 0.290 (0.050) 0.093 (0.062) 0.270 (0.051) 
Hong Kong (Validation) 0.365 (0.102) 0.388 (0.102) 0.300 (0.098) 0.138 (0.116) 0.320 (0.092) 
Japan 0.154 (0.034) 0.182 (0.040)    
U.S. 0.177 (0.040) 0.225 (0.042)    
China 0.166 (0.025) 0.313 (0.128)    
Italy 0.076 (0.025) 0.104 (0.029)    
^tdAUC (2 years) 
Hong Kong (Derivation) 0.736 (0.025) 0.763 (0.023) 0.709 (0.023) 0.644 (0.028) 0.740 (0.025) 
Hong Kong (Validation) 0.745 (0.049) 0.755 (0.049) 0.699 (0.050) 0.673 (0.054) 0.726 (0.053) 
Japan 0.661 (0.025) 0.680 (0.024)    
U.S. 0.682 (0.026) 0.718 (0.025)    
China 0.692 (0.022) 0.750 (0.058)    
Italy 0.614 (0.023) 0.653 (0.023)    
Standard errors (SE) were estimated from 200 bootstrap samples* or from the iid-representation of the estimator^. tdAUC, areas under time-
dependent receiver operating characteristic curve 
AJCC TNM, American Joint Committee on Cancer Tumor-Node-Metastasis; ERASL, Early Recurrence After Surgery for Liver tumor; 
SLICER, Singapore Liver Cancer Recurrence; tdAUC, areas under time-dependent receiver operating characteristic curve 
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Build statistical model that stratifies 
patients according to risk of early 
recurrence
*Graphical Abstract
 Highlights: 
 
 Recurrence is frequent within two years of surgical resection of hepatocellular 
carcinoma. 
 
 In this large international collaboration, we identify readily available, clinical 
parameters which influence such recurrence. 
 
 A simple and extensively validated statistical model that permits the risk of early 
recurrence to be estimated, is presented in the form of an online calculator. 
 
 This facility will enhance patient counselling about the likely success of the treatment 
and will help in design of adjuvant clinical trials. 
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